Ameriprise’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Ameriprise’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-17,428	Closed	-$75K	–	3751
2017 Q4	$75K	Sell	17,428 -24,500	-58%	-$117K	﹤0.01%	3577
2017 Q3	$59K	Sell	41,928 -35,528	-46%	-$49.5K	﹤0.01%	3629
2017 Q2	$117K	Sell	77,456 -55,814	-42%	-$120K	﹤0.01%	3644
2017 Q1	$343K	Buy	133,270 +28,110	+27%	+$65K	﹤0.01%	3296
2016 Q4	$268K	Buy	105,160 +25,750	+32%	+$73.9K	﹤0.01%	3537
2016 Q3	$245K	Buy	79,410 +775	+1%	+$2.42K	﹤0.01%	3498
2016 Q2	$252K	Buy	78,635 +13,245	+20%	+$48.5K	﹤0.01%	3453
2016 Q1	$202K	Buy	65,390 +3,370	+5%	+$11K	﹤0.01%	3532
2015 Q4	$249K	Sell	62,020 -440	-0.7%	-$2.03K	﹤0.01%	3565
2015 Q3	$286K	Buy	62,460 +13,040	+26%	+$68.2K	﹤0.01%	3498
2015 Q2	$256K	Buy	49,420 +13,490	+38%	+$80.9K	﹤0.01%	3716
2015 Q1	$225K	Buy	+35,930	New	+$207K	﹤0.01%	3538
2014 Q4	–	Sell	-135	Closed	-$1K	–	4782
2014 Q3	$1K	Sell	135 -4,485	-97%	-$30.6K	﹤0.01%	5641
2014 Q2	$30K	Sell	4,620 -8,400	-65%	-$94.6K	﹤0.01%	4138
2014 Q1	$310K	Buy	13,020 +10	+0.1%	+$145	﹤0.01%	3092
2013 Q4	$139K	Sell	13,010 -1,899	-13%	-$21K	﹤0.01%	3284
2013 Q3	$198K	Hold	14,909	–	–	﹤0.01%	3182
2013 Q2	$196K	Buy	+14,909	New	+$201K	﹤0.01%	3097

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Ameriprise's ECYT Position: Q1 2018 in Review

Ameriprise sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 17,428 shares — an estimated $75K sold.

Ameriprise first reported a position in ECYT in Q2 2013 and held it in 18 quarters. The position peaked at $343K in Q1 2017. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

Ameriprise reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Ameriprise sold 17,428 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $75K.
Ameriprise first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
Ameriprise's Endocyte, Inc. Common Stock position peaked at $343K in Q1 2017.
89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Ameriprise's 13F filing for Q1 2018, filed 15 May 2018.